Program
Pan-KRAS Inhibitor TLN-372
Also written as “TLN-372”, “TLN-372 in combination with cetuximab” and “TLN-372 in combination with pembrolizumab”.
Its studies are led by Treeline Biosciences.
Furthest: phase 1, since Sep 24, 20251 company-led study, 1 open or runningNext primary completion: Dec 3, 2031 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Treeline Biosciences | 11 open or running | phase 1since Sep 24, 2025 | Sep 24, 2025 | Dec 3, 2031phase 1 · NCT07204340 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2025First study: phase 1 study in KRAS Mutant Solid TumorsFirst studyNCT07204340 · 270 planned · United States, Australia, Canada and more
Ahead
- Dec 3, 2031Primary completion: phase 1 study in KRAS Mutant Solid TumorsNCT07204340
TargetBeta
KRAS →read by rule
“A small molecule inhibitor of KRAS mutations, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07204340KRAS Mutant Solid Tumors · United States, Australia, Canada and more | 1 | Recruiting | Dec 3, 2031 | 270 |
How it is read
Names in the registry
- “TLN-372”, 1 entry
- “TLN-372 in combination with cetuximab”, 1 entry
- “TLN-372 in combination with pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.